Outcomes With Venetoclax 50 mg, Hypomethylating Agents, and Voriconazole or Posaconazole in Acute Myeloid Leukemia

Outcomes With Venetoclax 50 mg, Hypomethylating Agents, and Voriconazole or Posaconazole in Acute Myeloid Leukemia

ABSTRACT Background Real‐world evidence for hypomethylating agent (HMA) + venetoclax 50 mg (VEN50) with voriconazole and posaconazole in acute myeloid leukemia (AML), is limited. Methods We evaluated outcomes of patients with newly‐diagnosed AML treated with HMA + VEN50 with either posaconazole (n =...

Full description

Saved in:
Bibliographic Details
Main Authors: Kendall Diebold, Devan Parker, Sarah Worth, Manuel Espinoza‐Gutarra, Pankit Vachhani, Kimo Bachiashvili, Sravanti Rangaraju, Razan Mohty, Ravi Bhatia, Omer Jamy
Format: Article
Language:English
Published: Wiley 2025-06-01
Series:eJHaem
Subjects:
acute myeloid leukemia (AML)
posaconazole
Venetoclax 50 mg
voriconazole
Online Access:https://doi.org/10.1002/jha2.70049
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:ABSTRACT Background Real‐world evidence for hypomethylating agent (HMA) + venetoclax 50 mg (VEN50) with voriconazole and posaconazole in acute myeloid leukemia (AML), is limited. Methods We evaluated outcomes of patients with newly‐diagnosed AML treated with HMA + VEN50 with either posaconazole (n = 23) or voriconazole (n = 95). Results We report that treatment with HMA + VEN50 with either azole elicits a response rate similar to that described in the VIALE‐A trial. Reducing the VEN dose to 50 mg with either strong CYP3A4 inhibitor did not compromise on the efficacy of the combination. Conclusion HMA + VEN50 with either posaconazole or voriconazole yields comparable responses to higher doses of VEN reported previously. Clinical trial registration The authors have confirmed clinical trial registration is not needed for this submission.
ISSN:2688-6146

Similar Items